CPT code 86593 denotes a laboratory serologic assay that evaluates the level of syphilis-related antibodies in patient specimens. As a targeted diagnostic test for Treponema pallidum exposure, this code supports clinical decision-making for screening, diagnosis, and monitoring of syphilis and has implications for public health surveillance and sexually transmitted infection management nationwide. Payers commonly involved in coverage of this laboratory service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

This publication provides a concise overview of clinical context for CPT code 86593, expected sites of service, and the types of benchmarks and policy considerations readers can expect to find, including reimbursement benchmarks, common billing and coding considerations, and payer coverage patterns. The report also highlights relevant clinical applications—screening, confirmatory testing, and monitoring response to therapy—and situates the test within common laboratory workflows. Data not provided in the input are noted where applicable. Readers will gain a clear understanding of what CPT code 86593 represents, which payers are typically relevant to coverage discussions, and which operational and policy topics are most pertinent for laboratory managers, billing professionals, and clinical leaders.